Pharma BD Deal Intelligence
A $210M bolt-on for a Cambridge biotech's DNA-repair science became Lynparza — the first approved PARP inhibitor, a multi-billion-dollar franchise, and the cornerstone of AstraZeneca's oncology turnaround.
Full analysis, sources & comparables →AstraZeneca acquired KuDOS for $210M cash, gaining a recognized DNA-repair / PARP inhibitor expert group and a clinical and preclinical pipeline complementing…
KuDOS, founded by Steve Jackson, developed olaparib through first-in-human trials before the AstraZeneca acquisition; the program ultimately reduced disease…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca acquires KuDOS for $210M; gains DNA-repair/PARP inhibitor platform - basis for olaparib (Lynparza).
A $210M bolt-on for a Cambridge biotech's DNA-repair science became Lynparza — the first approved PARP inhibitor, a multi-billion-dollar franchise, and the cornerstone of AstraZeneca's oncology turnaround.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited (this deal) | 2005 | $210M | 98 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2005 deals · AstraZeneca PLC deals